PGT-A, or Preimplantation Genetic Testing for Aneuploidies, is a laboratory procedure that allows fertility specialists to analyze embryos created through in vitro fertilization (IVF) before they are transferred into the uterus. This process involves extracting a few cells from the embryo at the blastocyst stage to assess whether it has the correct number of chromosomes.
Having an abnormal number of chromosomes—known as aneuploidy—is a common cause of failed IVF cycles, miscarriages, and genetic disorders. By identifying embryos with normal chromosomal makeup, PGT-A fertility testing gives patients the best chance of a healthy pregnancy and baby.
This test does not alter or damage the embryo. It simply provides valuable information that helps fertility specialists make more informed decisions about which embryo to transfer first.
Contents
When and why is PGT-A recommended?
There are specific clinical situations in which PGT-A fertility testing is particularly beneficial. These include:
- Women aged 35 and older, who are at higher risk of producing embryos with chromosomal abnormalities
- Individuals or couples with a history of recurrent pregnancy loss
- Patients who have experienced two or more failed IVF attempts
- Cases of male infertility or severely abnormal sperm
- Couples pursuing IVF with donor eggs or donor sperm
- Families at risk of passing on chromosomal rearrangements or genetic syndromes
In these scenarios, using PGT-A fertility testing can help prevent the emotional and physical toll of repeated failed transfers or early miscarriages. It can also reduce the number of IVF cycles needed to achieve a successful pregnancy, saving time, emotional energy, and financial resources.
Advantages of PGT-A fertility testing
The benefits of incorporating PGT-A fertility testing into an IVF cycle can be significant. Among them:
- Increased implantation rates by selecting chromosomally normal embryos
- Reduced miscarriage rates due to lower risk of transferring embryos with aneuploidies
- Improved success rates per IVF cycle
- Decreased chances of transferring embryos with potential genetic abnormalities
- Safer pregnancies through elective single embryo transfer, avoiding the risks of twins or multiples
PGT-A is not mandatory for every IVF patient but is a valuable tool in creating more personalized and effective fertility care.
Are there risks or limitations?
While the technology is advanced and generally safe, PGT-A is not a one-size-fits-all solution. Not every patient produces enough embryos for testing, and in rare cases, embryos may not survive the biopsy or freezing process. Additionally, PGT-A does not screen for all genetic conditions—only chromosomal number abnormalities. It’s also important to consider the added financial cost and time that the testing may introduce to the treatment plan.
That’s why consultation with a fertility specialist is essential to determine whether this test aligns with your reproductive goals and specific medical circumstances.
At PMH Fertility Center, we are committed to guiding you with compassion, precision, and care throughout your fertility journey.
Want to know if PGT-A fertility testing is the right choice for your IVF treatment?
Reach out to us at pmhfertility@puntamitahospital.com for expert advice and a personalized consultation.